Effects of paeonol on intracellular calcium concentration and expression of RUNX3 in LoVo human colon cancer cells

Li,Ming; Tan,Shi‑Yun; Zhang,Jun; You,Hong‑Xia

doi:10.3892/mmr.2013.1372

Effects of paeonol on intracellular calcium concentration and expression of RUNX3 in LoVo human colon cancer cells

Authors:
- Ming Li
- Shi‑Yun Tan
- Jun Zhang
- Hong‑Xia You
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: March 14, 2013 https://doi.org/10.3892/mmr.2013.1372
Pages: 1425-1430

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paeonol, a major phenolic component of the root bark of Paeonia moutan, is known to exhibit antitumor effects. However, the underlying mechanisms remain unknown. In the present study, the effects of paeonol on cell viability, intracellular calcium concentration and the expression of runt‑related transcription factor 3 (RUNX3) were analyzed in LoVo human colon cancer cells. Results revealed that paeonol markedly reduced LoVo cell viability in a time‑ and dose‑dependent manner. Flow cytometry assays demonstrated that paeonol blocked the cell cycle at the G1 to S transition and significantly induced apoptosis in LoVo cells. Intracellular calcium accumulation occurred following a 48 h treatment with paeonol. Furthermore, RUNX3 gene expression was increased in paeonol‑treated cells. These observations indicate that paeonol possesses antiproliferative properties and apoptosis‑inducing activity. One of the antitumor mechanisms of paeonol may be its apoptosis‑inducing activity through an increased intracellular calcium concentration and the upregulation of RUNX3 expression. Paeonol may be a promising antitumor agent for colon carcinoma treatment.

View Figures

View References

1	Strimpakos AS, Cunningham D, Mikropoulos C, Petkar I, Barbachano Y and Chau I: The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol. 21:1013–1019. 2010. View Article : Google Scholar : PubMed/NCBI
2	Riley CM and Ren TC: Simple method for the determination of paeonol in human and rabbit plasma by high-performance liquid chromatography using solid-phase extraction and ultraviolet detection. J Chromatogr. 489:432–437. 1989. View Article : Google Scholar
3	Chou TC: Anti-inflammatory and analgesic effects of paeonol in carrageenan-evoked thermal hyperalgesia. Br J Pharmacol. 139:1146–1152. 2003. View Article : Google Scholar : PubMed/NCBI
4	Huang H, Chang EJ, Lee Y, Kim JS, Kang SS and Kim HH: A genome-wide microarray analysis reveals anti-inflammatory target genes of paeonol in macrophages. Inflamm Res. 57:189–198. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hsieh CL, Cheng CY, Tsai TH, Lin IH, Liu CH, Chiang SY, Lin JG, Lao CJ and Tang NY: Paeonol reduced cerebral infarction involving the superoxide anion and microglia activation in ischemia-reperfusion injured rats. J Ethnopharmacol. 106:208–215. 2006. View Article : Google Scholar : PubMed/NCBI
6	Kim SA, Lee HJ, Ahn KS, Lee HJ, Lee EO, Ahn KS, Choi SH, Jung SJ, Kim JY, Baek N and Kim SH: Paeonol exerts anti-angiogenic and anti-metastatic activities through downmodulation of Akt activation and inactivation of matrix metalloproteinases. Biol Pharm Bull. 32:1142–1147. 2009. View Article : Google Scholar : PubMed/NCBI
7	Kim SH, Kim SA, Park MK, Kim SH, Park YD, Na HJ, Kim HM, Shin MK and Ahn KS: Paeonol inhibits anaphylactic reaction by regulating histamine and TNF-alpha. Int Immunopharmacol. 4:279–287. 2004. View Article : Google Scholar : PubMed/NCBI
8	Sun YC, Shen YX and Sun GP: Advances in the studies of major pharmacological activity of paeonol. Zhong Cheng Yao Zazhi. 26:579–582. 2004.(In Chinese).
9	Chen B, Ning M and Yang G: Effect of paeonol on antioxidant and immune regulatory activity in hepatocellular carcinoma rats. Molecules. 17:4672–4683. 2012. View Article : Google Scholar : PubMed/NCBI
10	Li N, Fan LL, Sun GP, Wan XA, Wang ZG, Wu Q and Wang H: Paeonol inhibits tumor growth in gastric cancer in vitro and in vivo. World J Gastroenterol. 16:4483–4490. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lee HJ, Kim SA, Lee HJ, Jeong SJ, Han I, Jung JH, Lee EO, Zhu S, Chen CY and Kim SH: Paeonol oxime inhibits bFGF-induced angiogenesis and reduces VEGF levels in fibrosarcoma cells. PLoS One. 5:e123582010. View Article : Google Scholar : PubMed/NCBI
12	Wan XA, Sun GP, Wang H, Xu SP, Wang ZG and Liu SH: Synergistic effect of paeonol and cisplatin on oesophageal cancer cell lines. Dig Liver Dis. 40:531–539. 2008. View Article : Google Scholar : PubMed/NCBI
13	Xing G, Zhang Z, Liu J, Hu H and Suqiura N: Antitumor effect of extracts from moutan cortex on DLD-1 human colon cancer cells in vitro. Mol Med Rep. 3:57–61. 2010.PubMed/NCBI
14	Ye JM, Deng T and Zhang JB: Influence of paeonol on expression of COX-2 and p27 in HT-29 cells. World J Gastroenterol. 15:4410–4414. 2009. View Article : Google Scholar : PubMed/NCBI
15	LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for cancer. Oncogene. 27:6252–6275. 2008. View Article : Google Scholar : PubMed/NCBI
16	Wang S: The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene. 27:6207–6215. 2008. View Article : Google Scholar : PubMed/NCBI
17	Huang WS, Wang JP, Wang T, Fang JY, Lan P and Ma JP: ShRNA-mediated gene silencing of beta-catenin inhibits growth of human colon cancer cells. World J Gastroenterol. 13:6581–6587. 2007. View Article : Google Scholar : PubMed/NCBI
18	Kaufmann SH and Hengartner MO: Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 11:526–534. 2001. View Article : Google Scholar : PubMed/NCBI
19	Clapham DE: Intracellular calcium. Replenishing the stores. Nature. 375:634–635. 1995. View Article : Google Scholar : PubMed/NCBI
20	Bootman MD, Berridge MJ and Roderick HL: Calcium signalling: more messengers, more channels, more complexity. Curr Biol. 12:R563–R565. 2002. View Article : Google Scholar : PubMed/NCBI
21	Kruman I, Guo Q and Mattson MP: Calcium and reactive oxygen species mediate staurosporine-induced mitochondrial dysfunction and apoptosis in PC12 cells. J Neurosci Res. 51:293–308. 1998. View Article : Google Scholar : PubMed/NCBI
22	Martikainen P, Kyprianou N, Tucker RW and Isaacs JT: Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res. 51:4693–4700. 1991.PubMed/NCBI
23	Bangsow C, Rubins N, Glusman G, Bernstein Y, Negreanu V, Goldenberg D, Lotem J, Ben-Asher E, Lancet D, Levanon D and Groner Y: The RUNX3 gene - sequence, structure and regulated expression. Gene. 279:221–232. 2001. View Article : Google Scholar : PubMed/NCBI
24	Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K and Salto-Tellez M: Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 1796:315–331. 2009.PubMed/NCBI
25	Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS, Lee CW, Voon DC, Koo JK, Wang H, Fukamachi H and Ito Y: RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell. 14:226–237. 2008. View Article : Google Scholar : PubMed/NCBI
26	Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB and Herman JG: Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis. 29:895–904. 2008. View Article : Google Scholar : PubMed/NCBI
27	Lee JM, Kwon HJ, Bae SC and Jung HS: Lung tissue regeneration after induced injury in Runx3 KO mice. Cell Tissue Res. 341:465–470. 2010. View Article : Google Scholar : PubMed/NCBI
28	Lee KS, Lee YS, Lee JM, Ito K, Cinghu S, Kim JH, Jang JW, Li YH, Goh YM, Chi XZ, Wee H, Lee HW, Hosoya A, Chung JH, Jang JJ, Kundu JK, Surh YJ, Kim WJ, Ito Y, Jung HS and Bae SC: Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer. Oncogene. 29:3349–3361. 2010. View Article : Google Scholar : PubMed/NCBI
29	Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG, Salto-Tellez M and Putti TC: RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat. 113:113–121. 2009. View Article : Google Scholar
30	Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, Hiong KC, Peh BK, Han HC, Ito T, Teh M, Yeoh KG and Ito Y: RUNX 3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res. 65:7743–7750. 2005.PubMed/NCBI
31	Li QL, Ito K, Sakakura C, Fukamachi H, Inoue KI, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 109:113–124. 2002. View Article : Google Scholar : PubMed/NCBI
32	Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E and Lothe RA: Gene methylation profiles of normal mucosa and benign and malignant colorectal tumors identify early onset markers. Mol Cancer. 7:942008. View Article : Google Scholar : PubMed/NCBI
33	Subramaniam MM, Chan JY, Soong R, Ito K, Yeoh KG, Wong R, Guenther T, Will O, Chen CL, Kumarasinghe MP, Ito Y and Salto-Tellez M: RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am J Gastroenterol. 104:426–436. 2009. View Article : Google Scholar : PubMed/NCBI
34	Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL, Kim HR, Cha EJ, Kaneda A, Ushijima T, Kim WJ, Ito Y and Bae SC: RUNX3 suppresses gastric epithelial cell growth by inducing p21^WAF1/Cip1 expression in cooperation with transforming growth factor β-activated SMAD. Mol Cell Biol. 25:8097–8107. 2005. View Article : Google Scholar : PubMed/NCBI
35	Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang L, Le X, Yao J, Wu TT, Huang S and Xie K: Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 65:4809–4816. 2005. View Article : Google Scholar
36	Müller I, Lipp P and Thiel G: Ca²⁺ signaling and gene transcription in glucose-stimulated insulinoma cells. Cell Calcium. 52:137–151. 2012.